Primary Image

Intensive Attention Training To Treat Brain Fog In Individuals With Long-COVID

Clinical Trial

Intensive Attention Training to Treat Brain Fog in Individuals with Long-COVID

IRB Protocol Number STU00220499

Contact

Katy Magee M.H.S., CCC-SLP/LCBIS LongCovid@sralab.org

Objective

The goal of this study is to test the feasibility and effectiveness of an attention training intervention as a potential treatment for brain fog symptoms (forgetfulness, confusion, or lack of focus) experienced by people with Long-Covid. 

Participants in this study will be asked to complete 2-4 sessions in which their memory and thinking abilities will be tested (2 hours each).

Depending on the group they are allocated to, most participants will also be instructed on how to complete a computerized program that aims to improve attention. They will be working on this program at home for 40 min a day, 5 days a week, for 4 weeks. During this time, they will meet with a speech therapist three times per week, at least one meeting per week will be in person at Shirley Ryan AbilityLab. 

Please fill out the screening survey to see if you qualify for the study. 

Start Survey

Who Can Participate

  • Between 18-65 years of age.
  • A history of confirmed Covid-19 infection.
  • Long-Covid brain fog symptoms (for example: forgetfulness, confusion, or lack of focus) starting on or shortly after the Covid-19 diagnosis.
  • Long-Covid brain fog symptoms interfere with everyday activities, and last at least 4 weeks. 
  • Able to participate in treatment once a week at Shirley Ryan Ability lab for 6 weeks over 2 months.
  • Proficiency in English. 

Compensation

Participants will receive monetary compensation for their participation.

 

Apply for this Trial

Your information will not be published.

All fields are required.

Featured Quote

More Studies

Brain-Based and Clinical Phenotyping of Pain Pharmacotherapy in Knee Osteoarthritis (PREDICT)

This is a clinical trial of people who have pain due to knee osteoarthritis at Northwestern University Feinberg School of Medicine in collaboration with Shirley Ryan AbilityLab. The study will last for about 20 weeks. 180 qualified participants will be randomly assigned in a 1:1:1 ratio (60 participants per group) to one of three treatment groups: duloxetine, celecoxib or placebo. Participants will have an X-ray, knee MRI, brain MRI, blood draws, pain sensitivity testing and will be asked to fill out questionnaires. The purpose of this study is to predict which participants will respond to the treatment.

read more
view all

Latest Updates

view all